A clear upregulation of both PD-1 (on CD4 and CD8 T-cells) as well as PD-L1 (on tumor cells and CD4 and CD8 T-cells) was detected in response to CEA-TCB treatment, indicative of the PD-1/PD-L1 axis being one of the adaptive resistance mechanisms related to TCB activity (8, 9, 25–29). The gene discussed is CD274; the disease is neoplasm.